AstraZeneca Book Value Per Share from 2010 to 2024

AZN Stock

USD 67.04 0.58 0.86%

AstraZeneca PLC Book Value Per Share yearly trend continues to be very stable with very little volatility. Book Value Per Share is likely to grow to 26.31 this year. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of AstraZeneca PLC ADR according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

25.05834762

Current Value

26.31

Quarterly Volatility

7.10995862

Credit Downgrade

Yuan Drop

Covid

Check AstraZeneca PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AstraZeneca PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.2 B, Interest Expense of 1.7 B or Total Revenue of 24.2 B, as well as many indicators such as Price To Sales Ratio of 4.37, Dividend Yield of 0.0285 or PTB Ratio of 5.12. AstraZeneca financial statements analysis is a perfect complement when working with AstraZeneca PLC Valuation or Volatility modules.

Check out the analysis of AstraZeneca PLC Correlation against competitors.

Latest AstraZeneca PLC's Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of AstraZeneca PLC ADR over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. AstraZeneca PLC's Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AstraZeneca PLC's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 26.27 X

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Book Value Per Share

Timeline

AstraZeneca Book Value Per Share Regression Statistics

	Arithmetic Mean	16.64
	Geometric Mean	13.96
	Coefficient Of Variation	42.74
	Mean Deviation	5.52
	Median	15.57
	Standard Deviation	7.11
	Sample Variance	50.55
	Range	26.753
	R-Value	0.60
	Mean Square Error	35.04
	R-Squared	0.36
	Significance	0.02
	Slope	0.95
	Total Sum of Squares	707.72

AstraZeneca Book Value Per Share History

	2024	26.31
	2023	25.06
	2022	23.94
	2021	27.71
	2020	11.92
	2019	11.22
	2018	11.08

Other Fundumenentals of AstraZeneca PLC ADR

Tangible Book Value Per Share

AstraZeneca PLC Book Value Per Share component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Capital Stock	Common Stock	Intangible Assets	Long Term Debt	Good Will	Property Plant Equipment	Current Deferred Revenue	Net Receivables	Net Tangible Assets	Long Term Investments	Short Long Term Debt	Deferred Long Term Liab	Long Term Debt Total	Capital Surpluse	Net Invested Capital	Net Working Capital
Total Assets		0.9	0.85	-0.24	-0.25	-0.36	0.96	0.69	0.83	0.74	0.74	0.96	0.79	1.0	0.83	0.5	0.75	-0.66	0.69	-0.36	0.6	0.68	0.63	0.8	0.09
Total Stockholder Equity	0.9		0.65	-0.03	-0.37	-0.22	0.74	0.76	0.81	0.69	0.69	0.82	0.57	0.91	0.65	0.47	0.67	-0.3	0.41	0.01	0.26	0.48	0.51	0.84	-0.04
Net Debt	0.85	0.65		-0.67	-0.4	-0.53	0.89	0.34	0.78	0.65	0.65	0.9	0.81	0.86	0.87	0.61	0.8	-0.83	0.84	-0.46	0.82	0.83	0.7	0.81	0.15
Retained Earnings	-0.24	-0.03	-0.67		0.51	0.55	-0.36	0.15	-0.34	-0.38	-0.38	-0.37	-0.51	-0.26	-0.57	-0.61	-0.66	0.6	-0.71	0.37	-0.68	-0.57	-0.64	-0.5	-0.27
Accounts Payable	-0.25	-0.37	-0.4	0.51		0.36	-0.15	-0.19	-0.41	-0.37	-0.37	-0.23	-0.23	-0.25	-0.43	-0.72	-0.63	0.0	-0.29	-0.28	-0.16	-0.29	-0.53	-0.66	-0.12
Short Term Investments	-0.36	-0.22	-0.53	0.55	0.36		-0.42	0.1	-0.33	-0.22	-0.22	-0.47	-0.4	-0.36	-0.39	-0.44	-0.47	0.44	-0.49	0.36	-0.41	-0.43	-0.44	-0.43	-0.09
Total Liab	0.96	0.74	0.89	-0.36	-0.15	-0.42		0.58	0.76	0.69	0.69	0.96	0.86	0.95	0.86	0.48	0.72	-0.82	0.82	-0.57	0.76	0.74	0.66	0.7	0.17
Total Current Assets	0.69	0.76	0.34	0.15	-0.19	0.1	0.58		0.45	0.81	0.81	0.55	0.63	0.67	0.63	0.3	0.56	-0.12	0.39	-0.01	0.24	0.33	0.53	0.59	0.25
Short Term Debt	0.83	0.81	0.78	-0.34	-0.41	-0.33	0.76	0.45		0.58	0.58	0.8	0.51	0.86	0.7	0.56	0.72	-0.51	0.6	-0.1	0.49	0.7	0.6	0.78	-0.33
Capital Stock	0.74	0.69	0.65	-0.38	-0.37	-0.22	0.69	0.81	0.58		1.0	0.72	0.87	0.74	0.86	0.48	0.82	-0.47	0.72	-0.25	0.59	0.54	0.77	0.81	0.27
Common Stock	0.74	0.69	0.65	-0.38	-0.37	-0.22	0.69	0.81	0.58	1.0		0.72	0.87	0.74	0.86	0.48	0.82	-0.47	0.72	-0.25	0.59	0.54	0.77	0.81	0.27
Intangible Assets	0.96	0.82	0.9	-0.37	-0.23	-0.47	0.96	0.55	0.8	0.72	0.72		0.82	0.97	0.81	0.46	0.72	-0.78	0.73	-0.47	0.68	0.66	0.59	0.8	0.11
Long Term Debt	0.79	0.57	0.81	-0.51	-0.23	-0.4	0.86	0.63	0.51	0.87	0.87	0.82		0.78	0.9	0.45	0.77	-0.77	0.86	-0.56	0.83	0.67	0.74	0.71	0.45
Good Will	1.0	0.91	0.86	-0.26	-0.25	-0.36	0.95	0.67	0.86	0.74	0.74	0.97	0.78		0.82	0.5	0.75	-0.66	0.69	-0.35	0.59	0.68	0.63	0.82	0.04
Property Plant Equipment	0.83	0.65	0.87	-0.57	-0.43	-0.39	0.86	0.63	0.7	0.86	0.86	0.81	0.9	0.82		0.69	0.9	-0.69	0.93	-0.4	0.83	0.83	0.91	0.8	0.24
Current Deferred Revenue	0.5	0.47	0.61	-0.61	-0.72	-0.44	0.48	0.3	0.56	0.48	0.48	0.46	0.45	0.5	0.69		0.87	-0.28	0.65	-0.02	0.43	0.52	0.86	0.66	0.12
Net Receivables	0.75	0.67	0.8	-0.66	-0.63	-0.47	0.72	0.56	0.72	0.82	0.82	0.72	0.77	0.75	0.9	0.87		-0.5	0.83	-0.2	0.63	0.69	0.95	0.87	0.2
Net Tangible Assets	-0.66	-0.3	-0.83	0.6	0.0	0.44	-0.82	-0.12	-0.51	-0.47	-0.47	-0.78	-0.77	-0.66	-0.69	-0.28	-0.5		-0.81	0.8	-0.89	-0.64	-0.47	-0.44	-0.2
Long Term Investments	0.69	0.41	0.84	-0.71	-0.29	-0.49	0.82	0.39	0.6	0.72	0.72	0.73	0.86	0.69	0.93	0.65	0.83	-0.81		-0.61	0.91	0.8	0.88	0.62	0.23
Short Long Term Debt	-0.36	0.01	-0.46	0.37	-0.28	0.36	-0.57	-0.01	-0.1	-0.25	-0.25	-0.47	-0.56	-0.35	-0.4	-0.02	-0.2	0.8	-0.61		-0.61	-0.32	-0.25	-0.07	-0.33
Deferred Long Term Liab	0.6	0.26	0.82	-0.68	-0.16	-0.41	0.76	0.24	0.49	0.59	0.59	0.68	0.83	0.59	0.83	0.43	0.63	-0.89	0.91	-0.61		0.79	0.68	0.48	0.21
Long Term Debt Total	0.68	0.48	0.83	-0.57	-0.29	-0.43	0.74	0.33	0.7	0.54	0.54	0.66	0.67	0.68	0.83	0.52	0.69	-0.64	0.8	-0.32	0.79		0.71	0.61	0.02
Capital Surpluse	0.63	0.51	0.7	-0.64	-0.53	-0.44	0.66	0.53	0.6	0.77	0.77	0.59	0.74	0.63	0.91	0.86	0.95	-0.47	0.88	-0.25	0.68	0.71		0.72	0.19
Net Invested Capital	0.8	0.84	0.81	-0.5	-0.66	-0.43	0.7	0.59	0.78	0.81	0.81	0.8	0.71	0.82	0.8	0.66	0.87	-0.44	0.62	-0.07	0.48	0.61	0.72		0.13
Net Working Capital	0.09	-0.04	0.15	-0.27	-0.12	-0.09	0.17	0.25	-0.33	0.27	0.27	0.11	0.45	0.04	0.24	0.12	0.2	-0.2	0.23	-0.33	0.21	0.02	0.19	0.13

Click cells to compare fundamentals

About AstraZeneca PLC Financial Statements

AstraZeneca PLC investors utilize fundamental indicators, such as Book Value Per Share, to predict how AstraZeneca Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Book Value Per Share	25.06	26.31
Tangible Book Value Per Share	(12.14)	(11.53)

Pair Trading with AstraZeneca PLC

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.

Moving against AstraZeneca Stock

0.88	VRNA	Verona Pharma PLC	Pair Corr
0.84	ETON	Eton Pharmaceuticals	Pair Corr
0.82	ELDN	Eledon Pharmaceuticals Downward Rally	Pair Corr
0.68	EWTX	Edgewise Therapeutics	Pair Corr
0.63	DSGN	Design Therapeutics	Pair Corr

The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.

The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether AstraZeneca PLC ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AstraZeneca PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Astrazeneca Plc Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Astrazeneca Plc Adr Stock:

How To Invest In AstraZeneca

Details

Is AstraZeneca Stock a good investment?

Details

What is AstraZeneca PLC's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of AstraZeneca PLC Correlation against competitors.

You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.034

Dividend Share

2.97

Earnings Share

2.08

Revenue Per Share

2.7424

Quarterly Revenue Growth

0.18

The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

AstraZeneca Book Value Per Share from 2010 to 2024

Latest AstraZeneca PLC's Book Value Per Share Growth Pattern

AstraZeneca Book Value Per Share Regression Statistics

AstraZeneca Book Value Per Share History

Other Fundumenentals of AstraZeneca PLC ADR

AstraZeneca PLC Book Value Per Share component correlations

About AstraZeneca PLC Financial Statements

Pair Trading with AstraZeneca PLC

Moving against AstraZeneca Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY